Abstract:Unlike many other diagnostic tests, a negative exome sequencing does not rule out a genetic disorder; instead, it only implies that a genetic diagnosis could not be identified, given the clinical and genetic information available at the time of analysis. Reanalyzing exome data from unsolved cohorts with neurodevelopmental disorders (NDD) holds significant importance for several reasons [1]. Firstly, it allows for the identification of potentially missed or misclassified genetic variants. The initial analysis of exome data may have been limited by the available knowledge at the time, as well as the algorithms and filtering strategies employed. Revisiting the data with improved variant calling algorithms and updated databases can unmask previously concealed genomic variations and lead to the discovery of disease-causing variants that were initially overlooked. Secondly, the reanalysis provides an opportunity to evaluate diagnostic variants according to current standards and guidelines [2]. Over time, our understanding of variant pathogenicity and gene-disease associations evolves, necessitating a reassessment of previously reported variants. By applying updated classification criteria and incorporating additional evidence, such as functional studies or confirmatory publications, the pathogenicity of variants can be more accurately determined. Furthermore, reanalyzing exome data allows for the confirmation or removal of gene-disease associations (GDA). As new research emerges, some previously reported associations may be called into question or require further validation. By critically evaluating the evidence supporting the GDAs, we refine our understanding of the genetic basis of NDD and establish more reliable genotype-phenotype correlations. Lastly, reanalysis can uncover previously unknown gene associations. The constantly expanding knowledge base of gene-disease relationships, with hundreds of new associations being identified each year, provides a valuable resource for revisiting unsolved cohorts. By leveraging this wealth of information and employing advanced computational tools and filtering strategies, researchers can identify novel gene candidates and establish their role in NDD.

Unveiling the hidden: revisiting the potential of old genetic data for rare disease research